Clinical Trials Browser

Completed × sacituzumab govitecan × Genitourinary × Clear all

NCT05226117 2026-03-27

Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer

Phase 2 Completed

Carcinoma, Transitional Cell

NCT03869190 2026-01-22

Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

Phase 1/2 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04527991 2025-08-03

TROPiCS-04

Phase 3 Completed

Locally Advanced or Metastatic Unresectable Urothelial Cancer

NCT04381832 2025-07-22

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

Phase 1/2 Completed

Prostatic Neoplasms, Castration-Resistant

NCT01631552 2021-08-12

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

Phase 1/2 Completed

515 enrolled 28 charts 3 FDA

BreastCNSGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms